Objective: To investigate the association of uncoupling protein-2 (UCP2) -866G > A gene polymorphism (rs659366) with nonalcoholic fatty liver disease (NAFLD).
among patients with type 2 diabetes mellitus (T2DM). [9] [10] [11] The prevalence of NAFLD among populations with obesity has been reported as being 50% to 80%. 12 Genetic and environmental factors are independent predictors of the initiation and progression of NAFLD. 13 It has been estimated that the obvious genetic participation in the development of NAFLD is 39%. 12 Uncoupling protein 2 (UCP2; NM_003355.2), one of the most important obesity-and diabetes-related proteins, 14 is part of the mitochondrial anion transporter protein family 15 and is recognized as a member of the mitochondrial carrier superfamily. UCP2 is expressed in several tissues, such as adipose tissue, and is one of the key regulators of energy balance. 14 UCP2 acts as a mediator of proton leakage across the inner cell membrane by uncoupling of substrate oxidation from adenosine triphosphate (ATP) synthesis; the final consequence is heat production and reduced ATP synthesis. 14, 16, 17 In the genomic region containing the UCP2 and UCP3 genes ( Figure 1 ), single nucleotide polymorphism (SNP) -866G>A is located in the proximal promoter region of the UCP2 gene on chromosome 11q13 in humans. 2, 16, 17 In several studies, this polymorphism has been associated with obesity and T2DM, possibly via inflammatory mediators.
14, [18] [19] [20] Therefore, it is conceivable that UCP2 is included in the progression and pathogenesis of NAFLD because of its close relationship with obesity and excess energy 15 and may provide a therapeutic objective for obesity and T2DM based on metabolic imbalance and oxidative damage. 16 In the current study, we aimed to evaluate the associations between -866G>A polymorphism of the UCP2 gene with NAFLD and its association with anthropometric variables, body composition, and metabolic parameters in patients with NAFLD who are overweight and obese.
Materials and Methods

Subjects and Study Design
We performed the present case-control study with a cohort of 151 participants, including 75 patients with NAFLD and 76 healthy individuals. The patients were selected from those referred to the outpatient clinics of Tabriz University of Medical Sciences, Tabriz, Iran, and disease diagnosis was confirmed by a physician according to ultrasonography findings.
The inclusion criteria were as follows: having body mass index (BMI; calculated as weight in kg divided by height in m 2 ) between 25 and 39, age between 20 years and 50 years, and any alcohol consumption. The exclusion criteria were as follows: using medications including metformin, corticosteroids, amiodarone, and/or valproate in the past 3 months; any history of acute and chronic liver diseases, viral hepatitis, hemochromatosis, or Wilson disease; any autoimmune or endocrine disorders; pregnancy or lactation; and having participated in weight loss diets for at least 3 months before the start of the screening process for this study.
Ethical Considerations
We obtained written informed consent from all subjects before their participation in the study. The study protocol was Figure 1 Genomic organization of the -866 G/A UCP2 region. The UCP2-UCP3 gene cluster maps in humans. ATG: start codon, TGA: stop codon. 
Anthropometric Assessments
We measured weight using a calibrated scale to the nearest 0.1 kg while subjects were wearing minimal clothing and not wearing shoes. Height was measured with a nonstretchable measuring tape with a precision level of 0.1 cm. We measured waist circumference (WC) at halfway between the lower ribcage and the higher iliac and hip circumference (HC) at the level of the maximum circumference over the gluteal region with nonelastic measuring tape. Waist-to-hip ratio (WHR) was calculated as WC divided by HC.
Body Composition Analysis
We assessed body composition via bioelectrical impedance analysis (BIA; Tanita BC-418, Tanita Corporation). The BIA device with 8 contact electrodes calculates the distinct body mass for various body segments, including the arms, legs, and trunk. Before the analysis, the subjects had fasted for 12 hours and had avoided heavy physical activity, alcohol consumption, and diuretic intake. We performed the assessment while subjects wore lightweight clothing and no shoes or jewelry. 21 
Biochemical Assessment
We performed all biochemical assays after the subjects had fasted for 12 hours. We obtained 7 cc of venous blood specimens from subjects. We transferred 2 cc of the collected blood into tubes containing ethylenediaminetetraacetic acid (EDTA) for genetic assays. Serum specimens were also extracted for biochemical assays. Measurement of fasting serum glucose (FSG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) concentrations was performed using kits on the Abbott ALCYON 300 autoanalyzer (Abbott Laboratories, Inc). All of the biochemical assays were performed by a trained laboratory assistant who was masked regarding group assignments. Levels of serum low-density lipoprotein cholesterol (LDL-C) were determined by using the Friedewald formula:
LDL-C ¼ TC -(HDL-C -TG/5). 22 
DNA Extraction and Genotyping
We isolated genomic DNA from the blood cells using the salting-out method. 23 This technique is a simple deproteinization cell procedure that involves dehydration and precipitation with saturated NaCl solution. In our experiments, 2 cc of blood was mixed with Triton lysis buffer (1% Triton X100, 5mM MgCl2, 0.32 M sucrose, 10mM trisaminomethane [Tris] -HCl, pH 7 and H2O as needed to thin out the mixture), and then the resulting product was spun down and washed with 100 mL Tris-EDTA buffer. The pellet was incubated with proteinase K at 60 C and subsequently salted out at 4 C using a saturated NaCl solution. We used centrifugation to remove precipitated proteins. The DNA was dissolved in 500 lL of distilled water (dH 2 O). We used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for SNP detection. DNA fragments analogous to the UCP2 gene -866 G>A (rs659366) polymorphism were amplified by primers: 5 0 -CACGCTGCTTCTGCCAGGAC-3 0 as forward primer and 5 0 -AGGCGTCAGGAGATGGACCG-3 0 as reverse primer. The polymerase chain reaction (PCR) primer sequences were designed using Gene Runner software (version 3.01), based on GenBank coding DNA reference sequence NM_003355.2:c.-1245G>A from the National Center for Biotechnology Information (NCBI) website http:// www.ncbi.nlm.nih.gov. The nomenclature used for nucleotide-acid sequence variation is based on established Human Genome Variation Society (HGVS) guidelines that can be found online at www.hgvs.org/content/guidelines. PCR was provided in a volume of 25 mL of specimen material containing 1 mL genomic DNA, 0.2 unit of Taq DNA polymerase, and 1 mL from each primer, which were added to 22 mL of 1x PCR master mix. The PCR procedure included a primary denaturation at 95 C for 5 minutes, followed by 38
cycles of denaturation at 94 C for 1 minute, annealing at 59 C for 1 minute, extension at 72 C for 46 seconds, and a final extension at 72 C for 5 minutes. The PCR products were run for visualization on 1% agarose gel and stained via ethidium bromide. PCR products in 10 mL volume and 2 mL buffer R were digested by 0.3 mL MluI restriction enzyme, incubated at 37 C for 1.5 hours, and electrophoresed on 2% agarose gel.
Statistical Analysis
We performed all data analysis using SPSS software (Statistical Package for the Social Sciences; SPSS Inc). The normality of variables was assessed via KolmogorovSmirnov test. Variables are expressed as mean (SD) or numbers and percentages. The comparison of continuous variables between 2 groups was performed by independentsample t-testing. We performed comparison of continuous variables between different UCP-2 genotypes by analysis of covariance (ANCOVA) with adjustment for the confounder effects of age and sex. Also, categorical variables were compared using the v2 test. We used logistic regression analysis to assess the relationship between anthropometric and biochemical variables, with NAFLD genotypes adjusted for the confounding roles of sex and age. P <.05 was considered to be statistically significant.
Results
General demographic, anthropometric, and biochemical parameters of the study population are presented in Table 1 . Mean (SD) age, BMI, and body composition values were not statistically significantly different between the NAFLD and control groups; however, WC and WHR values in patients with NAFLD were significantly higher, compared with the healthy control group (P <.05). Serum concentrations of HDL-C and LDL-C were significantly lower in patients with NAFLD, whereas serum AST, ALT, and TG concentrations were significantly higher in patients with NAFLD (P <.05 and P <.01 respectively). We observed a high prevalence of the AG and GG genotypes of UCP2 polymorphism in the NAFLD and control groups, whereas the dominant genotypes in the NAFLD and control groups were AG (57.3%) and GG (48.7%), respectively ( Table 2) .
Image 1 presents the UCP2 -866G>A polymorphism assessment using the PCR-RFLP method. respectively) ( Table 4) . Comparison of the study parameters according to -866G>A of the UCP2 gene polymorphism between patients with NAFLD and the healthy control group is presented in Table 5 . In subjects with the GG genotype, serum TG concentrations were significantly higher in patients with NAFLD. Serum ALT concentrations in all 3 genotypes and serum AST concentrations in the AG and GG genotypes of UCP2 gene polymorphism were significantly higher in patients with NAFLD, compared with the healthy control group (P <.05).
Discussion
In the current case-control study, we report high prevalence of the AG and GG genotypes of UCP2 gene polymorphisms in patients with NAFLD and healthy subjects (57.3% and 36.0%, respectively; and 46.1% and 48.7%, respectively). To our knowledge, this report is the first to evaluate the prevalence of -866G>A UCP2 gene polymorphism (rs659366) and its association with anthropometric and biochemical variables in patients with NAFLD.
The findings of our study are in agreement with the findings of the study by Tayeb, 24 which report higher occurrence of AG (43%) and GG (37%), compared with the AA (20%) In our study, WC and ALT values were more highly significant potent predictors of NAFLD occurrence. Serum TG concentrations were higher in patients with NAFLD who had the GG genotype. Serum ALT concentrations in all 3 genotypes and serum AST concentrations in the AG and GG genotypes of UCP2 gene polymorphism were higher in patients with NAFLD, compared with healthy subjects. We performed these comparisons after adjusting for age and sex (P <.05).
Waist circumference as a marker of central obesity is related to fat, excess free-fatty-acid concentrations, and metabolic syndrome. 28 Two study reports 28, 29 have revealed high WC values in 42% to 44% of patients with NAFLD. In a study by Rocha et al, 28 the results revealed a strong association between increased WC and metabolic syndrome among patients with NAFLD (P <.001). The results of another study by Clark et al 30 also showed a significant association between high aminotransferase and WC values and higher BMI. In addition, elevated ALT levels have been associated with general and central obesity and elevated triglyceride concentrations. 28, 30 In the current study, we discovered also that other anthropometric and biochemical parameters were not associated with genotypes of the UCP2 gene. Similar findings were reported by D'Adamo et al 25 and Heidari et al, 14 whereas no association among BMI, WHR, lipid profile and genotypes of UCP2 -866AG polymorphism in 76 individuals with diabetes mellitus and 76 individuals with obesity was reported. These discrepancies in the findings of numerous studies can be attributed to the modest effect of this polymorphism, which is more likely to be confounded by different environmental and lifestyle modifiers. Larger sample sizes could be helpful in obtaining more relevant findings. Additionally, several other parameters, such as sex hormones (ie, estrogen or testosterone), might attenuate these relationships, as previously reported by Peric as et al 31 and Rodriguez et al. 32 
Conclusion
Our findings showed a modest modifier effect of -866G>A UCP2 polymorphism (rs659366) in patients with NAFLD.
Further studies with large-scale data are needed to confirm our results and to provide stronger clarification of the associations that we mention herein. Several limitations of the current study are as follows: we did not control the possible confounder effects of nutritional intake and physical activity in our study. Also, we did not achieve significant results in several findings, which might be attributed to our relatively low sample size. Nevertheless, we believe that our findings contribute to the scientific understanding of the role of genetic polymorphisms in diagnosing NAFLD. LM
